(1071–1093) Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

Sunday, November 13, 2022

9:00 AM – 10:30 AM Eastern Time

Location: Virtual Poster Hall

All of the relevant financial relationships listed for faculty have been mitigated.

Poster abstract session.

Presentations:

9:00 AM – 10:30 AM Eastern Time

Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab
Abstract Poster Presenter: Arielle Mendel, MD, FRCPC, MSc – McGill University Health Centre
9:00 AM – 10:30 AM Eastern Time

Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Abstract Poster Presenter: Adil Vural, MD – Cleveland Clinic Fairview Hospital
9:00 AM – 10:30 AM Eastern Time

Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Abstract Poster Presenter: Soko Kawashima, MD, PhD – Kyorin University
9:00 AM – 10:30 AM Eastern Time

Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis
Abstract Poster Presenter: Berengere Molina, MD – University de Bretagne Occidentale
9:00 AM – 10:30 AM Eastern Time

Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Abstract Poster Presenter: Lee Baylis, MD – GlaxoSmithKline
9:00 AM – 10:30 AM Eastern Time

ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain
Abstract Poster Presenter: Naomi Patel, MD – Massachusetts General Hospital
9:00 AM – 10:30 AM Eastern Time

Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
Abstract Poster Presenter: Peter Merkel, MD, MPH – University of Pennsylvania
9:00 AM – 10:30 AM Eastern Time

Glucocorticoid Use and Related Adverse Events in ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis
Abstract Poster Presenter: Emil deGoma, MD – ChemoCentryx
9:00 AM – 10:30 AM Eastern Time

Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Abstract Poster Presenter: Fabricio Benavides, MD – Hospital Universitario MarquÃ©s de Valdecilla
9:00 AM – 10:30 AM Eastern Time

Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
Abstract Poster Presenter: Benjamin Terrier, MD, PhD – Cochin Hospital
9:00 AM – 10:30 AM Eastern Time

Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
Abstract Poster Presenter: Mike Putman, MD, MSc – The Medical College of Wisconsin
9:00 AM – 10:30 AM Eastern Time

Outcomes of Methotrexate as an Initial Induction and Maintenance Regimen for Localized Granulomatosis with Polyangiitis: A Retrospective Review
Abstract Poster Presenter: Pratyusha Banik, MD – Oregon Health & Science University
9:00 AM – 10:30 AM Eastern Time

Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide
Abstract Poster Presenter: Dario Roccatello, MD – UNIVERSITA' DEGLI STUDI DI TORINO
9:00 AM – 10:30 AM Eastern Time

Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
Abstract Poster Presenter: Xavier Puechal, MD, PhD – CHU
9:00 AM – 10:30 AM Eastern Time

Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort
Abstract Poster Presenter: Sharanya Joginpalli, MD – Baylor College of Medicine- Texas Children's Hospital
9:00 AM – 10:30 AM Eastern Time

Characteristics and Outcomes of Patients with ANCA Associated Vasculitis Treated with Plasma Exchange: An Analysis of the National Inpatient Sample Database
Abstract Poster Presenter: Vinit Gilvaz, MD – Brown University
9:00 AM – 10:30 AM Eastern Time

Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
Abstract Poster Presenter: Zachary Wallace, MD, MSc – Massachusetts General Hospital
9:00 AM – 10:30 AM Eastern Time

Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
Abstract Poster Presenter: Eveline Wu, MD, MSc – UNC Chapel Hill
9:00 AM – 10:30 AM Eastern Time

Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Abstract Poster Presenter: Chang Keun Lee, MD, PhD – Asan Medical Center
9:00 AM – 10:30 AM Eastern Time

Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
Abstract Poster Presenter: Johannes Dieterich, MD – Eberhard Karls Universität Tübingen
9:00 AM – 10:30 AM Eastern Time

IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study
Abstract Poster Presenter: Zachary Wallace, MD, MSc – Massachusetts General Hospital
9:00 AM – 10:30 AM Eastern Time

WITHDRAWN
9:00 AM – 10:30 AM Eastern Time

ANCA Associated Vasculitis: Online CME Improves Rheumatologists' Knowledge and Confidence
Abstract Poster Presenter: Natalie Guevara, MPH, DVM – WebMD